Drug Repurposing

Repurposed candidates have already passed Phase I clinical trials, providing extensive toxicology, pharmacokinetic, and dosing data. This pre-existing knowledge eliminates years of early-stage safety testing.

• Reduces clinical failure risk from ~90% to ~50%
• Enables accelerated regulatory review via 505(b)(2) pathway
• Leverages decades of post-marketing pharmacovigilance data

Modern repurposing relies on in silico methods that systematically match drugs to novel indications without wet-lab screening. Key approaches include:

• Transcriptomic signature matching against Connectivity Map databases
• Knowledge graph embedding to predict missing drug-disease links
• Molecular docking against off-target protein structures
• Electronic health record mining for real-world signal detection

Most drugs interact with multiple biological targets beyond their primary mechanism of action. Repurposing systematically exploits this polypharmacology by identifying therapeutically relevant off-target binding events.

• Kinase inhibitors often show cross-reactivity across the kinome
• GPCR-targeting drugs frequently modulate related receptor subtypes
• Network propagation algorithms map these secondary interactions to disease modules

Traditional drug development requires 10-15 years and $1-3 billion per approved drug. Repurposing compresses this to 3-6 years with costs of $300-500 million.

• Bypasses target discovery and lead optimization phases
• Existing manufacturing infrastructure reduces scale-up costs
• Known intellectual property landscape simplifies licensing negotiations

Historically, repurposing relied on serendipitous clinical observations (e.g., sildenafil for erectile dysfunction, thalidomide for leprosy). Modern approaches emphasize systematic computational prediction:

• Matrix factorization decomposes drug-disease association matrices
• Multi-task learning simultaneously predicts efficacy across indications
• Causal inference frameworks distinguish correlation from causation in observational data

Successful computational predictions require rigorous orthogonal validation before clinical translation. The regulatory framework differs from novel drugs:

• Retrospective EHR analysis confirms epidemiological signals
• In vitro target engagement assays verify predicted binding
• Animal disease models establish proof-of-concept efficacy
• FDA 505(b)(2) application leverages existing safety data

The design or functional capacity of a single drug molecule to interact with multiple distinct biological targets simultaneously. This inherent promiscuity is the mechanistic basis for most repurposing discoveries, as a drug's secondary 'off-target' interactions can produce a novel therapeutic effect. Computational polypharmacology modeling involves constructing drug-target interaction networks to map the full pharmacological profile of a compound, distinguishing between therapeutic targets and those responsible for side effect prediction.

A computational approach that compares a disease's gene expression pattern against a reference database of drug-induced gene expression changes. The core logic is to identify compounds that reverse the disease state at the transcriptional level. Key resources include:

• Connectivity Map (CMap): A reference collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules.
• LINCS L1000: A large-scale gene expression profiling project that measures the expression of 1,000 landmark genes to infer the full transcriptome, dramatically reducing the cost of signature generation.

A machine learning technique that projects the entities and relations of a biomedical knowledge graph into a low-dimensional vector space. By learning the structural patterns of existing drug-disease, drug-target, and gene-disease relationships, these embeddings can perform link prediction to infer missing connections. This allows the model to score and rank novel drug-disease associations that are geometrically plausible within the latent space, even if they have never been explicitly documented in the literature.

Clinical evidence derived from the analysis of real-world data (RWD), such as electronic health records (EHRs), insurance claims, and patient registries. In drug repurposing, electronic health record mining applies natural language processing to unstructured clinical notes to identify serendipitous signals—for example, detecting that patients taking a specific diabetes drug exhibit a lower-than-expected incidence of a neurodegenerative condition. This approach complements mechanistic modeling by providing population-scale, longitudinal observational data.

A statistical framework that goes beyond correlation to determine whether a specific drug exposure directly causes a particular therapeutic outcome. Unlike standard association mining, causal methods attempt to control for confounding variables. A prominent technique is Mendelian Randomization, which uses genetic variants as instrumental variables to mimic a randomized controlled trial. By leveraging naturally occurring genetic variation that modulates a drug target's activity, this method can provide stronger evidence for a repurposing hypothesis before committing to expensive clinical trials.

The computational identification of multi-drug regimens that produce a synergistic therapeutic effect greater than the sum of their individual effects. This is a critical extension of repurposing, as complex diseases often require polypharmacological intervention. Models predict a synergy score using frameworks like:

• Loewe Additivity: Assumes a drug cannot interact with itself.
• Bliss Independence: A probabilistic model based on independent action. These predictions guide the selection of repurposed drug pairs that can overcome resistance mechanisms or target parallel survival pathways.